Literature DB >> 11563402

Effects of glucocorticoids and cyclosporine on IL-2 and I kappa B alpha mRNA expression in human peripheral blood mononuclear cells.

W A Briggs1, S H Han, H Miyakawa, J F Burdick, H M Kwon.   

Abstract

To evaluate molecular mechanisms that might account for the heterogeneity in the in vitro responsiveness of individual subjects' peripheral blood mononuclear cells (PBMC) to immunosuppressive drugs, the authors quantitated in normal human cells the suppressive effects of the glucocorticoids prednisolone and methylprednisolone and of cyclosporine on interleukin-2 (IL-2) mRNA expression and IL-2 production, as well as the stimulatory effect of these drugs on IkappaBalpha mRNA expression. As expected, cyclosporine was significantly more suppressive than either glucocorticoid of IL-2 mRNA expression and IL-2 production by mitogen-stimulated PBMC, with variable degrees of inhibition in cells from individual subjects. The authors confirmed in human PBMC the stimulation of IkappaBalphamRNA expression by the glucocorticoid reported by others in HeLa and transfected Jurkat cell lines. In addition, the authors observed a stimulatory effect on IkappaBalpha mRNA expression by cyclosporine as well in 8 of 10 PBMC preparations studied, suggesting a possible role of calcineurin in the regulation of IkappaBalpha production. Interindividual variability in the intracellular mechanisms of action, possibly based on molecular polymorphisms, might be one factor contributing to differences among patients in their clinical responses to treatment with such drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11563402     DOI: 10.1177/00912709922007651

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  2 in total

1.  Up-regulation of interleukin-2 mRNA in children with idiopathic nephrotic syndrome.

Authors:  Hironobu Shimoyama; Mitsuru Nakajima; Hiroyuki Naka; Yoshiyuki Maruhashi; Hideki Akazawa; Taku Ueda; Masayuki Nishiguchi; Yoko Yamoto; Hidekazu Kamitsuji; Akira Yoshioka
Journal:  Pediatr Nephrol       Date:  2004-08-07       Impact factor: 3.714

2.  Remission of refractory minimal change nephrotic syndrome after basiliximab therapy.

Authors:  Sung-Shin Park; Won-Ho Hahn; Sung-Do Kim; Byoung-Soo Cho
Journal:  Pediatr Nephrol       Date:  2009-02-26       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.